April 6, 2019

The Effects of Early Nutritional Interventions on the Development of Atopic Disease in Infants and Children: The Role of Maternal Dietary Restriction, Breastfeeding, Hydrolyzed Formulas, and Timing of Introduction of Allergenic Complementary Foods

Frank R. GreerScott H. SichererA. Wesley BurksCOMMITTEE ON NUTRITIONSECTION ON ALLERGY AND IMMUNOLOGY
This clinical report updates and replaces a 2008 clinical report from the American Academy of Pediatrics, which addressed the roles of maternal and early infant diet on the prevention of atopic disease, including atopic dermatitis, asthma, and food allergy. As with the previous report, the available data still limit the ability to draw firm conclusions about various aspects of atopy prevention through early dietary interventions. Current evidence does not support a role for maternal dietary restrictions during pregnancy or lactation. Although there is evidence that exclusive breastfeeding for 3 to 4 months decreases the incidence of eczema in the first 2 years of life, there are no short- or long-term advantages for exclusive breastfeeding beyond 3 to 4 months for prevention of atopic disease. The evidence now suggests that any duration of breastfeeding ≥3 to 4 months is protective against wheezing in the first 2 years of life, and some evidence suggests that longer duration of any breastfeeding protects against asthma even after 5 years of age. No conclusions can be made about the role of breastfeeding in either preventing or delaying the onset of specific food allergies. There is a lack of evidence that partially or extensively hydrolyzed formula prevents atopic disease. There is no evidence that delaying the introduction of allergenic foods, including peanuts, eggs, and fish, beyond 4 to 6 months prevents atopic disease. There is now evidence that early introduction of peanuts may prevent peanut allergy.

European S2k Guideline on Chronic Pruritus

Elke Weisshaar, Jacek C. Szepietowski, Florence J. Dalgard, Simone Garcovich, Uwe Gieler, Ana M. Giménez-Arnau, Julien Lambert, Tabi Leslie, Thomas Mettang, Laurent Misery, Ekin Şavk, Markus Streit, Erwin Tschachler, Erwin Tschachler, Joanna Wallengren, Sonja Ständer
DOI: 10.2340/00015555-3164 

Abstract

Pruritus is a frequent symptom in medicine. Population-based studies show that every 5th person in the general population has suffered from chronic pruritus at least once in the lifetime with a 12-month incidence of 7%. In patient populations its frequency is much higher depending on the underlying cause, ranging from around 25% in haemodialysis patients to 100% in skin diseases such as urticaria and atopic dermatitis (AD). Pruritus may be the result of a dermatological or non-dermatological disease. Especially in non-diseased skin it may be caused by systemic, neurological or psychiatric diseases, as well as being a side effect of medications. In a number of cases chronic pruritus may be of multifactorial origin. Pruritus needs a precise diagnostic work-up. Management of chronic pruritus comprises treatment of the underlying disease and topical treatment modalities, including symptomatic antipruritic treatment, ultraviolet phototherapy and systemic treatment. Treating chronic pruritus needs to be targeted, multimodal and performed in a step-wise procedure requiring an interdisciplinary approach. We present the updated and consensus based (S2k) European guideline on chronic pruritus by a team of European pruritus experts from different disciplines. This version is an updated version of the guideline that was published in 2012 and updated in 2014 (www.euroderm.org).
Full Text HTML   -     PDF

April 2, 2019

Management of Ocular Allergy Itch With an Antihistamine-Releasing Contact Lens

Pall, Brian, OD, MS*; Gomes, Paul, MS; Yi, Frank, MS*; Torkildsen, Gail, MD

doi: 10.1097/ICO.0000000000001911
Clinical Science: PDF Only
OPEN
SDC
PAP
Purpose: A contact lens (CL)-based drug delivery system for therapeutic delivery of the antihistamine ketotifen was tested in 2 parallel, conjunctival allergen challenge-based trials.

April 1, 2019

Severe anaphylaxis after pelvic examination: a case report of dual latex and chlorhexidine allergies

  • Email author,
  • ,
  • ,
  • ,
  • ,
  •  and

Abstract

Background
Natural rubber latex and chlorhexidine have previously been identified as causative substances in perioperative anaphylaxis. A pelvic examinations is generally considered noninvasive, however, this procedure is rarely associated with severe allergic reactions.

March 29, 2019

World Allergy Congress Lyon 2019 : Novel therapies in skin allergic diseases.


ANT CONGRES
 
FOCUS ON OUR PLENARY SESSIONS
 
“Novel therapies in skin allergic diseases”
 
Atopic dermatitis (AD) is the most prevalent skin allergy. Not surprisingly, there has been increasing interest in developing experimental approaches to study the pathogenesis of human AD in vivo, in vitro, and in silico to better define pathophysiologic mechanisms and identify novel therapeutic targets and biomarkers that predict therapeutic response. 

March 26, 2019

Physician Confidence in Artificial Intelligence: An Online Mobile Survey

Original Paper


1Division of Nephrology, Department of Internal Medicine, Soonchunhyang University Hospital, Seoul, Republic of Korea
2Department of Urology, Soonchunhyang University Hospital, Seoul, Republic of Korea
3Department of Orthopedic Surgery, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea
4Department of Internal Medicine, New York Medical College, New York Health Hospital, New York, NY, United States

ABSTRACT

Background: It is expected that artificial intelligence (AI) will be used extensively in the medical field in the future.
Objective: The purpose of this study is to investigate the awareness of AI among Korean doctors and to assess physicians’ attitudes toward the medical application of AI.

March 22, 2019

The Allergic Rhinitis Control Test Questionnaire Is Valuable in Guiding Step-Down Pharmacotherapy Treatment of Allergic Rhinitis

The Journal of Allergy and Clinical Immunology: In Practice




Background
Allergic Rhinitis Control Test (ARCT) has been validated in the allergic rhinitis (AR) step-up pharmacotherapy management approach.
Objective
The aim of our study was to evaluate the potential of ARCT in AR step-down pharmacotherapy.

March 20, 2019

A longitudinal study of cannabis use increasing the use of asthma medication in young Norwegian adults

  • Research article
  • Open Access
  • Open Peer Review
BMC Pulmonary Medicine
BMC Pulmonary Medicine201919:52
Open Peer Review reports

Abstract

Background
A small number of studies have shown that the use of cannabis increases the risk of bronchial asthma. There is, however, a paucity of longitudinal studies which are able to control for known risk factors of bronchial asthma.

Comparison of therapeutic effects of inhaled corticosteroids on three subtypes of cough variant asthma as classified by the impulse oscillometry system

  • Research
  • Open Access

Respiratory Research
Respiratory Research201920:41

Abstract

Background
Cough variant asthma (CVA) is one of the most common causes of chronic persistent cough, and early treatment with inhaled corticosteroids (ICSs) is recommended to attenuate the inflammation and remodeling.

March 15, 2019

Tumor necrosis factor-alpha and Fas/Fas ligand signaling pathways in chronic spontaneous urticaria

Abstract

Background
There is increasing evidence pointing to the important role of tumor necrosis factor-alpha (TNF-α), a key inflammatory and apoptotic mediator in urticarial inflammation. However, the role of the TNF-α system and Fas/Fas ligand (FasL) in the apoptosis-inducing pathways in chronic spontaneous urticaria (CSU), remain unclear.

March 13, 2019

Bronchoalveolar lavage cell profiles and proteins concentrations can be used to phenotype extrinsic allergic alveolitis patients

  • Original research article
  • Open Access

Martina Sterclova
  • ,
  • ,
  • ,
  •  and
  • Abstract

    Background
    Extrinsic allergic alveolitis (EAA) patients form heterogenous group with different clinical manifestation and different prognosis. We aimed to determine how to phenotype distinct EAA subgroups. Predictive role of the bronchoalveolar lavage fluid (BALF) IL-4Rα concentration at the time of diagnosis with regard to the clinical behavior in EAA patients was studied.

    March 8, 2019

    Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks

    • Email author,
    • ,
    • ,
    • ,
    • ,
    • ,
    •  and

    Abstract

    Introduction
    For prophylaxis of hereditary angioedema (HAE) attacks, replacement therapy with human C1-inhibitor (C1-INH) treatment is approved and available as intravenous [C1-INH(IV)] (Cinryze®) and subcutaneous [C1-INH(SC)] HAEGARDA®preparations. In the absence of a head-to-head comparative study of the two treatment modalities, an indirect comparison of data from 2 independent but similar clinical trials was undertaken.